● Single award · contract
BPS - Advance the Development of V920, a Vaccine Against Ebola Virus Using a Recombinant Vesicular Stomatitis…
A single federal award, with both ends of the trail linked.
$65.1M
total award value
2016
action date
97 mo
period
HHSO100201600031C
PIID
Description
BPS - Advance the Development of V920, a Vaccine Against Ebola Virus Using a Recombinant Vesicular Stomatitis Virus Vector. Igf::ot::igf
Awarding agencyDepartment of Health and Human Services →
RecipientMerck Sharp & Dohme LLC →
Place of performanceIowa →
CategoryNAICS 541711PSC AN13
Competed?Not recorded✓ from source
Total (exact)$65,103,309
More awards to Merck Sharp & Dohme LLC
awarded 2021$2.2B
awarded 2017$1.5B
awarded 2017$236.3M
awarded 2024$155.8M
awarded 2021$102.3M
More from Department of Health and Human Services
awarded 2024$100.1B
awarded 2023$92B
awarded 2022$80.5B
awarded 2021$80.5B
awarded 2022$71.7B
🔎
Why the labels? The graph is only worth anything if the links are trusted. Facts taken straight from a federal filing are ✓ from source; anything we compute or infer (corporate parents, districts, competitors) is ≈ inferred and worded carefully, never asserted as fact.